Japan Pharmaceuticals & Healthcare Report Q1 2008

Publication Date	December 2007
Publisher	Business Monitor
Product Type	Report
Pages	99
ISBN Number	1748-197X
Product Code	BMI01044

Buy this product or for assistance call +44 20 7060 7474

PDF £425.00$707 | €476

FAX Order above formats by FAX

Summary

Valued at an impressive US$64bn, Japan has the world's second largest pharmaceutical market and, accordingly, is of great interest to drugmakers. However, there exist numerous challenges to operating in the country, including sluggish growth, delays in the introduction of innovative medicines, severe downward pressure on prices and reimbursement, and a culture of over-prescribing. In response to the farreaching April 2006 price cuts, the Japan Pharmaceutical Manufacturers Association (JPMA) proposed a new drug pricing system in July 2007 for the National Health Insurance (NHI) price list, in order to strengthen international competitiveness and establish appropriate drug prices in the market, although this has yet to have an impact on the market.

Like many other industries in the country, the pharmaceuticals sector poses substantial barriers to entry for foreign firms, so multinationals frequently form joint-ventures with local players. Importantly, the market is dynamic - as illustrated by Japan's top spot in the BMI's adjusted Business Environment Ranking table - and reforms to pricing transparency and the encouragement of generic drugs will provide upside to enlightened players.

Consequently, BMI marginally upgraded its projection for Japan's generic drug market in July 2007 after a basket of medicines lost patent protection and public knowledge of the benefit of this type of pharmaceutical improved. Moreover, the spread of flat-sum reimbursement schemes, a number of fee changes and increased co-payments for drugs over the past few years have also had an effect. A key change in 2006 was the introduction of a tick box on script forms, allowing doctors to indicate their approval of substitution. BMI fully expects the uptake of generics in Japan to continue, with the value of the sub-sector reaching US$10.36bn in 2013, or 14.7% of the total pharmaceutical market.

While Japan's overall pharmaceutical market is stagnating, sales of antidepressants are increasingly rapidly as the stigma attached to this class of drugs, and mental health in general, decreases. A surge in advertising by pharmaceutical firms beginning in the late 1990s is partly responsible, as well as the cultural shift during the recent economic downturn. BMI expects this strong growth to continue as suicide rates continue to rise and the phenomenon of hikikomori or acute social withdrawal increases.

Content

Japan Pharmaceuticals And Healthcare Industry SWOT
Japan Political SWOT
Japan Economic SWOT
Business Environment Ranking
Pharmaceutical Ratings: Revised Methodology
Ratings Overview
Weighting
Japan - Business Environment Ranking
Pharmaceutical Market
Country Structure
Limits To Potential Returns
Market Risk
Country Risk
Risks To Potential Returns
Japan - Market Summa13
Regulatory Regime
Case Study: Wyeth's Prevnar and Japanese Drug-Lag
Recent Regulatory Developments
Medical Device Regulations
Intellectual Property Developments
Intellectual Property Disputes
Pricing And Reimbursement System
Recent Pricing And Reimbursement Developments
Other Regulatory Issues
Industry Trends And Developments
Health Profile
Depression
Cancer
Healthcare Sector
Healthcare Sector Finance Issues
Healthcare Reforms
Pharmaceutical Industry
International Collaboration
Pharmaceutical Sector Policy
International Reaction
Domestic Company Activity
Generics Sector
Foreign Generic Sector
Multinational Sector Developments
Research And Development
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors - Industry
Macroeconomic Forecast Scenario
Prescription Market Forecast
OTC Market Forecast
Generics Market Forecast
Patented Medicines Market Forecast
Export/Import Forecasts
Other Healthcare Data And Forecasts
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Company Profiles
Leading Foreign Manufacturers
Pfizer
Sanofi-Aventis
Merck & Co (Banyu)
Novartis
GlaxoSmithKline (GSK)
AstraZeneca
Indigenous Manufacturers
Takeda
Astellas
Eisai
Daiichi-Sankyo
Sawai Pharmaceutical
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Sources
List of Tables
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components
- Table: Business Environment Rankings
- Table: Reimbursement Categories And Rates
- Table: Mortality By Cause In Japan
- Table: Japan - Recent Pharmaceutical Industry Mergers And Acquisitions
- Table: Share Repurchasing At The Leading Japanese Drugm
- Table: Concerns Of Pharmaceutical Associations
- Table: Timeline: Indian Manufacturers In Japan, 2005-2006
- Table: Japanese Ethical Market- Leading Therapeutic Classes, FY05/06
- Table: Japan's Drug Market Indicators
- Table: Japan Healthcare Expenditure Indicators
- Table: Japan - Macroeconomic Forecasts
- Table: Prescription Drug Market Indicators (US$mn unless otherwise stated)
- Table: OTC Market Indicators (US$mn unless otherwise stated)
- Table: Generics Market Trends
- Table: Patented Medicines Market Indicators
- Table: Export/Import Trends (US$mn)
- Table: Socio-Demographic Indicators
- Table: Japanese Ethical Market - Sales Value (FY2006)

Delivery Details

PDF:Immediate delivery

Ask a question about this product

Need help finding the right product?

Product features / use

Scope	Expert Insight/Opinion
Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted